IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET
Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J. , Sept. 13, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq:   IMNN) , a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and
September 13, 2023
IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET
Program will feature members of IMUNON executive management along with key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J. , Sept. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq:   IMNN) , a clinical-stage biotechnology company focused on developing DNA-mediated
September 7, 2023
IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla
Renowned scientist will advise on the development of IMUNON’s FixPlas and IndiPlas modalities in immuno-oncology LAWRENCEVILLE, N.J. , Aug. 14, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy
August 14, 2023